Antibody Clause Samples
The 'Antibody' clause defines the rights and obligations related to the use, development, or ownership of antibodies within a contract. Typically, this clause specifies which party retains ownership of any antibodies developed during the course of a project, outlines permitted uses (such as research, commercial, or diagnostic purposes), and may address issues like intellectual property rights or licensing. Its core practical function is to clearly allocate rights and responsibilities regarding antibodies, thereby preventing disputes over ownership or usage and ensuring both parties understand their respective positions.
POPULAR SAMPLE Copied 1 times
Antibody. For clarity, the Lead Success Factors for each Lead will include a requirement that the relevant Hit (or antibody that comprises the sequence of a Hit or is derived through Mutagenesis of a Hit) induces a functional response or response via an acceptable Target-specific mechanism.
Antibody. Subject to the terms and conditions of this Agreement and any license within the Novartis Patent Rights, Novartis and its Affiliates hereby grant to Regeneron and its Affiliates the right and license under the Novartis Intellectual Property to Co-Develop, Co-Commercialize and Co-Market the IL-1 Antibody Product throughout the IL-1 Antibody Territory for the Term of this Agreement with respect to the IL-1 Antibody Product. Such license shall be conditional upon the proper exercise by Regeneron of the IL-1 Antibody Opt-In Right and shall be co-exclusive with Novartis and its Affiliates only. The rights granted to Regeneron and its Affiliates hereunder shall not be sublicensable.
Antibody. The term “
Antibody. The term “Antibody” shall mean any antibody and any fragment thereof, including any protein or any fragments thereof and any non-protein based scaffold.
Antibody. Novartis shall be responsible for an amount equal to the product of the aggregate Development Costs for the IL-1 Antibody Product in the Co-Commercialization Countries for NAFTA for the relevant calendar quarter multiplied by fifty-five percent (55%), and Regeneron shall be responsible for an amount equal to the product of the aggregate Development Costs for the IL-1 Antibody Product in the Co-Commercialization Countries in NAFTA for the relevant calendar quarter multiplied by forty-five percent (45%). In the event that a Party has incurred less than its applicable percentage share of such Development Costs for an applicable calendar quarter, then, pursuant to Section 9.2(a), such Party shall reimburse the other Party in such amount as is necessary to result in each Party bearing its applicable share of such Development Costs for such calendar quarter.
Antibody. With respect to the IL-1 Antibody, all rights not specifically granted herein to Regeneron are expressly reserved to Novartis. For the avoidance of doubt, Novartis reserves all right, title and ownership to [*********************]. Nothing in this Agreement shall be interpreted as granting to Regeneron any rights with respect to [****************************************].
Antibody. Regeneron may terminate this Agreement with respect to the entire Territory for IL-1 Antibody Products, on (i) nine (9) months' written notice to Novartis at any time prior to the first Launch of such IL-1 Antibody Product in the IL-1 Antibody Territory; and (ii) twelve (12) months' written notice to Novartis at any time after the first Launch of such IL-1 Antibody Product in the IL-1 Antibody Territory. Except as otherwise provided below in this Section 19.4(b), the Agreement shall continue in full force and effect with respect to the IL-1 Antibody Product through the applicable notice period set forth above (the "IL-1 Antibody Termination Notice Period"), provided that Regeneron shall not be required to pay to Novartis any milestone payment in respect of the IL-1 Antibody Product which is achieved during the IL-1
Antibody. The term “First Antibody” shall mean, individually and collectively, the antibodies against PD-1 described in Exhibit B.
Antibody. Upon the first occurrence of each of the events set forth below, Regeneron shall pay to Novartis the corresponding amount set forth below: <TABLE> <CAPTION> -------------------------------------------------------- Milestone --------- Milestone Event Payment --------------- ------- -------------------------------------------------------- <S> <C> [****************************] [*******] -------------------------------------------------------- [***************************] [********] -------------------------------------------------------- [***************************] [********] -------------------------------------------------------- </TABLE> For the avoidance of doubt, each of the above milestones will be payable only once, but may occur in the same year.
Antibody. Novartis and its Affiliates shall be solely responsible, in Novartis's discretion, for the Development of the IL-1 Antibody Product through the End of Phase II Development and for all associated Development costs and expenses. Without limiting the foregoing, Novartis and its Affiliates shall have the right, exercisable in their sole discretion, to determine [*****************************************] and nothing in this Agreement shall be interpreted as granting to Regeneron any rights with respect to [*********************************].